QIAGEN N.V. Annual Report 2001

More documents

Recommendations

Info

10 Next Generation Drug Discovery: Genomics — Proteomics
— Cellomics QIAGEN — Focusing the Power of Life Sciences Genomic studies are yielding vast amounts of information and providing insights into the functions and interactions of individual genes — knowledge essential for detailed understanding of human diseases and development of biopharmaceutical drugs. Reliable methods for purification of high-quality nucleic acids are a prerequisite for genomic analyses and studies, and QIAGEN’s core technologies are dedicated to answering this need. In 2001, QIAGEN expanded its position in the genomics market by forming strategic alliances with companies such as KREATECH Biotechnology B.V. and Genicon Sciences Corporation, developing key enabling technologies for genomics to create and commercialize new multi-analyte detection technologies. Gene functions are mediated by proteins, whose properties, biological functions, and roles in disease must be characterized and understood. This understanding is being achieved through studies of protein-protein interaction and complexes to characterize entire proteomes. Accurate and complete protein characterization is based on detailed genomic information that must be verified by confirming the identity of the encoding gene sequence. Proteomic studies will be a major challenge for biomedical research in the next decade, complementing and linking with disciplines such as genetics, cell and molecular biology, protein chemistry, structural biology, and bioinformatics. QIAGEN produces a wide range of leading products for expression, purification, separation, and analysis of recombinant proteins, all of which are important tools for proteomics, and many of which are today setting the standard for research in these fields. In addition, QIAGEN’s core technologies for nucleic acid purification, separation, and handling are the basic tools for the genetic analyses that are integral to proteomic studies. Both genomics and proteomics have led to dramatic progress in our understanding of the chemistry of life and the study of disease processes to develop new drugs. They focus on studying genes and proteins in vitro, while diseases develop in living cells. Cellomics is the study of chemical and molecular interactions of cellular components, or the ”cellome”, and focuses on understanding the effect of drugs on the entire cell. This highly complex information must be verified by supporting proteomic and genomic analyses. QIAGEN recently introduced its first products linking cell separation with nucleic acid purification. QIAGEN’s core technologies are essential tools for genomic, proteomic, and cellomic studies, and we look forward to continuing to provide technology leadership and the highest quality support to the life sciences in the future. QIAGEN provides high-quality products for modern drug development 11
Page 1 and 2: QIAGEN N.V. Annual Report 2001 QIAG
Page 3 and 4: Financial Highlights Financial High
Page 5 and 6: Report of the Supervisory Board Eri
Page 7 and 8: Letter from the Managing Board To O
Page 9 and 10: QIAGEN — Focusing the Power of Li
Page 11: QIAGEN — Focusing the Power of Li
Page 19 and 20: SELECTED CONSOLIDATED FINANCIAL DAT
Page 21 and 22: RESULTS OF OPERATIONS The following
Page 23 and 24: Operon, and QIAGEN Sciences, Inc. (
Page 25 and 26: as a result, operating costs relate
Page 27 and 28: credit lines totaling $9.6 million
Page 29 and 30: $360,000, based on the year-end int
Page 31 and 32: QIAGEN N.V. AND SUBSIDIARIES CONSOL
Page 39 and 40: in affiliated companies that are 50
Page 41 and 42: n. Financial Instruments In the ord
Page 43 and 44: December 31, 2001 (January 1, 2001
Page 45 and 46: During 1997, the Company purchased
Page 47 and 48: On March 20, 1997, the Company sold
Page 49 and 50: As of December 31, 2001 and 2000, t
Page 51 and 52: Long-term debt consists of the foll
Page 53 and 54: The Company has elected to adopt SF
Page 55 and 56: 17. LICENSING AGREEMENTS The Compan
Page 57 and 58: Assets Germany United States Switze
Page 59 and 60: STATEMENTS OF INCOME FOR THE YEAR E
Page 61 and 62: 7. SHAREHOLDERS’ EQUITY The autho
Page 63 and 64:
OTHER INFORMATION 2. STATUTORY PROF
Page 65 and 66:
1977, Lecturer of Biophysical Chemi
Page 67 and 68:
Since June 27, 1996, the Common Sha
Page 69 and 70:
Corporate Headquarters QIAGEN N.V.
Page 71:
QIAGEN Investor Relations Dr. Solve
show all

QIAGEN N.V. Annual Report 2001

Create successful ePaper yourself

Delete template?

Save as template?